The Billion-Dollar Math Keeping New Drugs Off Shelves
We are treating harder diseases today and our old testing methods are not working anymore.
Sick people are waiting for cures while drug companies waste billions on failed trials. Fixing this broken system is the only way to make medicine affordable again.
Takeaways
Drug costs get more expensive every year.
Ninety percent of human clinical trials fail.
The easy medical breakthroughs are already done.
Expiring patents force companies to play safe.
Microchips are replacing traditional animal drug testing.
Why Drug Discovery Is Failing And How To Fix It
I spend my days working as a medical scientist at Biolife Health Center, looking at data for new treatments. I talk to a lot of people who ask why a new medicine costs so much. Or why it takes fifteen years to get a single pill from a lab to a pharmacy. Here's the thing. The system we use to invent drugs is broken.
We call it Eroom's Law. You know Moore's Law, the rule that says computer chips get faster and cheaper over time. Eroom's Law is the exact opposite. It says the cost to discover a new drug doubles about every nine years. Today, it takes roughly $2 billion and over a decade to bring one new therapy to the public.
And even with all that money, the success rate is terrible.
I've noticed a lot of frustration from patients who feel like we aren't moving fast enough. They see billions of dollars pouring into research labs. But they don't see cures for the diseases their families are facing. I think the pharmaceutical industry is stuck in an outdated model. I want to explain why, and how my colleagues and I across BioLife and its subsidiaries are trying to fix it.
The Empty Low-Hanging Fruit
In the past, scientists discovered massive, broad-stroke treatments. Think about the first antibiotics or standard heart medications. Those were the easy wins. The low-hanging fruit. We found them decades ago.
But today, we're trying to treat things like Alzheimer's and complex autoimmune diseases. These are tough, stubborn conditions. Because basic medicine already works so well, any new drug has to prove it's much safer or much better than what is already cheap and available. We call this the Better than the Beatles problem.
It's incredibly hard to write a better pop song than the Beatles. It's just as hard to make a better cholesterol pill than the cheap generics we already have.
Take pain management as a concrete example. We have aspirin and ibuprofen. They're incredibly cheap and they work for most minor pains. If I want to invent a brand new painkiller today, I have to spend a billion dollars to prove my new pill is significantly better than aspirin without causing any new side effects. That is a massive financial hurdle. It stops a lot of good research right in its tracks.
Why Ninety Percent Fail
So we run clinical trials. And most of them fail. About 90 percent of drug candidates that enter human trials never make it to the market. That's a staggering amount of wasted time and money.
Why does it happen? Sometimes, we pick the wrong target. A drug looks great in a computer model or works perfectly in a mouse. But a mouse isn't a human. The biology just doesn't carry over. I've seen researchers spend five years curing cancer in laboratory mice, only to watch the drug do absolutely nothing when given to a human patient.
Then you have drugs that simply don't work in people. Around 40 to 50 percent of drugs fail because they don't show enough benefit when we test them in a large human population. A drug might look promising in a test tube, but the human body is messy. We all have different genetics, diets, and stress levels.
And finally, you have unexpected toxicity. A compound might cure the disease but damage the liver. We usually don't find that out until late in the process, after we've already spent hundreds of millions of dollars testing it. I remember a specific trial for a promising arthritis medication. It reduced joint swelling beautifully. But in Phase III human trials, it caused severe heart palpitations in a small percentage of patients. We had to scrap the entire project. All that time and money just vanished.
The Patent Cliff
Then you have the financial reality of running a massive company. When a pharmaceutical company finally gets a successful drug approved, they hold a patent. That patent gives them exclusive rights to sell the drug and make their money back.
But patents expire. When that happens, cheap generic versions flood the market. The original company loses a massive chunk of revenue almost overnight. We call this the patent cliff. It terrifies investors. To survive the cliff, companies often stop taking big scientific risks.
Instead of trying to cure a completely new disease, they tweak an existing drug just enough to get a new patent. We call these me-too drugs.
A company might take a daily allergy pill and reformulate it into a 12-hour capsule. They make money, but they don't advance medicine. It's like releasing a slightly different version of the same smartphone every year instead of inventing a new technology.
Stopping The Guesswork
We can't keep working this way. The cost of failure is too high. So researchers across the private and public sector are changing the rules. We're moving away from trial and error.
We're starting to use New Approach Methodologies, or NAMs This is a simple way of saying we're building better test models. Instead of testing a new chemical on a mouse, we use organ-on-a-chip technology.
Imagine a clear plastic block about the size of a USB drive. Inside, we line tiny channels with living human lung cells or heart cells. We pump fluid through it to mimic human blood flow. Then we test the drug on that chip. It acts just like a real human organ.
If I want to test a new asthma drug, I don't give it to a rat. I put it into a lung-on-a-chip. I watch the human cells react in real time. I see if the cells get inflamed or if they relax. It gives us a highly accurate picture of whether a drug will be toxic or effective before we ever give it to a human patient. It stops us from wasting a billion dollars on a drug that was always going to fail.
Let me know if that makes sense.
FAQs
What is Eroom's Law?
It's the observation that drug discovery becomes slower and more expensive over time, despite constant improvements in technology.
Why do 90 percent of drugs fail in clinical trials?
Most fail because they don't work in humans or they cause unexpected toxicity that wasn't seen in earlier animal testing.
What is a "me-too" drug?
It's a drug that is structurally very similar to an already known drug, offering minor improvements rather than a brand-new medical breakthrough.
How does the "patent cliff" affect drug prices?
When a drug's patent expires, cheaper generic versions become available, causing a sharp drop in revenue for the original pharmaceutical company.
What is organ-on-a-chip technology?
It's a small device lined with living human cells that mimics the function of human organs to test how safe and effective a drug will be.
Citations
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191-200. https://en.wikipedia.org/wiki/Eroom%27s_law
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it?. Acta Pharmaceutica Sinica B, 12(7), 3049-3062. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 323(9), 844-853. https://pubmed.ncbi.nlm.nih.gov/32125404/
Jena, A. B., Calfee, J. E., Mansley, E. C., & Philipson, T. J. (2009). 'Me-too' innovation in pharmaceutical markets. Forum for Health Economics & Policy, 12(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659838/
Food and Drug Administration. (2026). New Approach Methodologies (NAMs). FDA. https://www.fda.gov/science-research/about-science-research-fda/new-approach-methodologies-nams
